CL2016001415A1 - Composiciones farmacéuticas que comprenden fumarato de dimetilo - Google Patents

Composiciones farmacéuticas que comprenden fumarato de dimetilo

Info

Publication number
CL2016001415A1
CL2016001415A1 CL2016001415A CL2016001415A CL2016001415A1 CL 2016001415 A1 CL2016001415 A1 CL 2016001415A1 CL 2016001415 A CL2016001415 A CL 2016001415A CL 2016001415 A CL2016001415 A CL 2016001415A CL 2016001415 A1 CL2016001415 A1 CL 2016001415A1
Authority
CL
Chile
Prior art keywords
dimethyl fumarate
pharmaceutical compositions
monosacarids
discsed
diluently
Prior art date
Application number
CL2016001415A
Other languages
English (en)
Inventor
Jimenez Maria Planells
Lopez Begoña Duarte
Coll Pere Guiro
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49917530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016001415(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of CL2016001415A1 publication Critical patent/CL2016001415A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>COMPOSICION FARMACEUTICA QUE COMPRENDE A) FUMARATO DE DIMETILO, B) UN DILUYENTE SELECCIONADO DE MONOSACARIDOS, DISACARIDOS Y ALMIDON, ENTRE OTROS, C) CELULOSA MICROCRISTALINA Y D) CROSCARMELOSA SODICA; METODO; Y USO PARA TRATAR O PREVENIR TRASTORNOS TALES COMO ARTRITIS REUMATOIDE, ESCLEROSIS MULTIPLE Y PSORIASIS, ENTRE OTROS.</p>
CL2016001415A 2013-12-12 2016-06-09 Composiciones farmacéuticas que comprenden fumarato de dimetilo CL2016001415A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382504 2013-12-12

Publications (1)

Publication Number Publication Date
CL2016001415A1 true CL2016001415A1 (es) 2017-01-20

Family

ID=49917530

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001415A CL2016001415A1 (es) 2013-12-12 2016-06-09 Composiciones farmacéuticas que comprenden fumarato de dimetilo

Country Status (31)

Country Link
US (2) US20160310457A1 (es)
EP (2) EP3079666B1 (es)
JP (3) JP6581088B2 (es)
KR (2) KR102335289B1 (es)
CN (2) CN105813634A (es)
AR (1) AR098746A1 (es)
AU (2) AU2014363792B2 (es)
BR (1) BR112016012179B1 (es)
CA (2) CA2932054C (es)
CL (1) CL2016001415A1 (es)
CY (1) CY1124336T1 (es)
DK (1) DK3079666T3 (es)
EA (1) EA201600457A1 (es)
ES (1) ES2860551T3 (es)
HK (1) HK1224212A1 (es)
HR (1) HRP20210468T1 (es)
HU (1) HUE054408T2 (es)
IL (2) IL287109B (es)
LT (1) LT3079666T (es)
MX (2) MX2016007105A (es)
MY (1) MY179355A (es)
NZ (2) NZ720287A (es)
PH (2) PH12016501043B1 (es)
PL (1) PL3079666T3 (es)
PT (1) PT3079666T (es)
RS (1) RS61658B1 (es)
SG (3) SG10201913076PA (es)
SI (1) SI3079666T1 (es)
TW (2) TWI704915B (es)
UA (2) UA120428C2 (es)
WO (1) WO2015086467A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
CA2939990C (en) 2014-02-28 2018-07-10 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US10085961B2 (en) 2015-06-01 2018-10-02 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
WO2016205754A1 (en) 2015-06-19 2016-12-22 University Of Southern California Compositions and methods for modified nutrient delivery
WO2017040272A1 (en) * 2015-08-31 2017-03-09 Banner Life Sciences Llc Fumarate ester dosage forms
WO2017114593A1 (en) * 2015-12-31 2017-07-06 Zaklady Farmaceutyczne Polpharma S.A. Process for preparation of an enteric coated granulate comprising dimethyl fumarate
EP3407873A1 (en) * 2016-01-28 2018-12-05 Zaklady Farmaceutyczne Polpharma SA Process for preparation of a granulate comprising dimethyl fumarate
AU2017216861A1 (en) * 2016-02-12 2018-10-04 Universität Zürich Dimethyl fumarate (DMF) for prevention or treatment of gout, acne, diabetes, vitiligo and/or pyoderma gangrenosum
WO2017145036A1 (en) * 2016-02-25 2017-08-31 Aurobindo Pharma Ltd Pharmaceutical compositions comprising dimethyl fumarate
CA3059293A1 (en) 2017-06-23 2018-12-27 Almirall, S.A. Pharmaceutical compositions comprising dimethyl fumarate
JP7000148B2 (ja) * 2017-12-27 2022-01-19 日本化薬株式会社 ダサチニブを有効成分とする医薬組成物
WO2020053218A1 (en) 2018-09-13 2020-03-19 Almirall, S.A. Treatment of psoriasis
WO2020053219A1 (en) 2018-09-13 2020-03-19 Almirall, S.A. Treatment of psoriasis
KR102197465B1 (ko) * 2019-05-31 2020-12-31 주식회사 큐라클 디메틸푸마르산염을 함유한 장용성 정제
BR112022007431A2 (pt) * 2019-11-07 2022-07-12 Asahi Chemical Ind Composição de celulose e comprimido
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
EP4313023A1 (en) * 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE19848260C2 (de) 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
PL2801354T3 (pl) 2004-10-08 2017-08-31 Forward Pharma A/S Kompozycje farmaceutyczne o kontrolowanym uwalnianiu zawierające ester kwasu fumarowego
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
PT1877059E (pt) * 2005-04-28 2010-05-04 Wyeth Llc Tanaproget micronizado e composições contendo o mesmo
WO2007042034A1 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
CN101304732A (zh) * 2005-10-07 2008-11-12 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
WO2007042035A2 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
WO2009118764A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Pharmaceutical composition comprising diclofenac and paracetamol
SI2379063T2 (sl) 2009-01-09 2021-09-30 Fwp Ip Aps Farmacevtska formulacija, ki obsega enega ali več estrov fumarne kisline v tableti v erozivnem matriksu
EP2379062A1 (en) 2009-01-09 2011-10-26 Forward Pharma A/S Pharmaceutical composition comprising one or more fumaric acid esters
EP2424357A4 (en) * 2009-04-29 2012-10-10 Biogen Idec Inc TREATMENT OF NERVOUS GENERATION AND NERVE IGNITION
AR086647A1 (es) * 2011-06-03 2014-01-15 Hoffmann La Roche Metodos para tratar el mesotelioma con un compuesto inhibidor de la pi3k
RU2014125430A (ru) 2011-11-24 2015-12-27 Синтон Бв Контролируемое высвобождение частиц, содержащих диметилфумарат
BR112014019462B1 (pt) * 2012-02-07 2022-03-22 Biogen Ma Inc. Composições farmacêuticas contendo fumarato de dimetila

Also Published As

Publication number Publication date
RS61658B1 (sr) 2021-04-29
MY179355A (en) 2020-11-05
CA3135273A1 (en) 2015-06-18
KR102353201B1 (ko) 2022-01-18
JP6945603B2 (ja) 2021-10-06
ES2860551T3 (es) 2021-10-05
TWI704915B (zh) 2020-09-21
HK1224212A1 (zh) 2017-08-18
AU2014363792A1 (en) 2016-06-09
SG10201913076PA (en) 2020-02-27
IL245685A0 (en) 2016-06-30
JP2021130689A (ja) 2021-09-09
AU2019268075A1 (en) 2019-12-12
IL287109A (en) 2021-12-01
UA123880C2 (uk) 2021-06-16
HUE054408T2 (hu) 2021-09-28
CA2932054A1 (en) 2015-06-18
MX2020009745A (es) 2020-10-08
TWI687218B (zh) 2020-03-11
IL245685B (en) 2021-10-31
US20210330628A1 (en) 2021-10-28
UA120428C2 (uk) 2019-12-10
EP3079666B1 (en) 2021-02-03
EP3656379A1 (en) 2020-05-27
CN114159421A (zh) 2022-03-11
JP6581088B2 (ja) 2019-09-25
KR20210150587A (ko) 2021-12-10
JP2019218385A (ja) 2019-12-26
BR112016012179B1 (pt) 2023-04-18
KR20160089397A (ko) 2016-07-27
EP3079666A1 (en) 2016-10-19
PH12019502610A1 (en) 2021-02-22
PH12016501043A1 (en) 2016-07-04
CY1124336T1 (el) 2022-07-22
SI3079666T1 (sl) 2021-04-30
IL287109B (en) 2022-08-01
CN105813634A (zh) 2016-07-27
JP2016540003A (ja) 2016-12-22
TW201605435A (zh) 2016-02-16
HRP20210468T1 (hr) 2021-05-14
BR112016012179A2 (es) 2017-08-08
CA2932054C (en) 2022-09-20
TW202011953A (zh) 2020-04-01
AU2019268075B2 (en) 2020-12-17
PT3079666T (pt) 2021-02-18
MX2016007105A (es) 2016-08-11
EA201600457A1 (ru) 2016-11-30
CN114159421B (zh) 2023-08-25
DK3079666T3 (da) 2021-03-22
KR102335289B1 (ko) 2021-12-06
NZ759411A (en) 2020-06-26
LT3079666T (lt) 2021-03-25
AU2014363792B2 (en) 2019-11-14
SG10201802815UA (en) 2018-05-30
PL3079666T3 (pl) 2021-09-06
US20160310457A1 (en) 2016-10-27
NZ720287A (en) 2020-05-29
WO2015086467A1 (en) 2015-06-18
AR098746A1 (es) 2016-06-08
PH12016501043B1 (en) 2016-07-04
SG10201913080VA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
CL2016001415A1 (es) Composiciones farmacéuticas que comprenden fumarato de dimetilo
BR112018013530A2 (pt) ?peptídeo isolado, polinucleotídeo e composição farmacêutica?
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
AU2019268062A1 (en) Benzoquinolone inhibitors of VMAT2
PH12016501151A1 (en) Nrf2 regulators
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
MX356368B (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CL2016002346A1 (es) Composiciones para modular la expresión de ataxina 2
MY194319A (en) Aldehyde compounds for treating pulmonary fibrosis, hypoxia, and connective tissue and autoimmune disease
UY34327A (es) ?composiciones y métodos para controlar malezas comprendiendo un polinucleótido y agente de transferencia, y que modulan 4-hidrofenil-piruvato-dioxigenasa?.
BR112016023815A2 (pt) composições tópicas para o alívio da dor, produção e uso
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
UY37018A (es) Inhibidores bicíclicos de pad4
ECSP13012573A (es) 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3
SV2016005230A (es) Derivados de acido heteroaril butanoico como inhibidores de lta4h
UY35488A (es) Xantinas sustituidas y métodos para su uso
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2016000073A (es) Composiciones y métodos para inhibir la expresión del gen alas1
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112017009289A2 (pt) métodos de administrar composições de amantadina
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios
PH12015502405B1 (en) Methods and compositions for wound healing